Skip to main content

HARVARD BIOSCIENCE INC

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

HBIO$9.09+8.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

(Unaudited, in thousands, except share and per share data)

September 30,December 31,
20252024
Assets
Current assets:
Cash and cash equivalents$6,817$4,108
Accounts receivable, net12,10914,866
Inventories21,60423,245
Other current assets3,2752,898
Total current assets43,80545,117
Property, plant and equipment, net4,9905,106
Operating lease right-of-use assets7,5006,132
Goodwill9,52556,324
Intangible assets, net8,37911,132
Other long-term assets3,7932,833
Total assets$77,992$126,644
Liabilities and Stockholders' Equity
Current liabilities:
Debt$33,967$36,956
Accounts payable5,1764,787
Contract liabilities2,8793,806
Other current liabilities12,3749,409
Total current liabilities54,39654,958
Deferred tax liability733710
Operating lease liabilities7,3326,381
Other long-term liabilities1,4631,255
Total liabilities63,92463,304
Stockholders' equity:
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized--
Common stock, par value $0.01 per share, 80,000,000 shares authorized: 44,579,665 shares issued and outstanding at September 30, 2025; 44,074,475 shares issued and outstanding at December 31, 2024446441
Additional paid-in-capital237,922236,579
Accumulated deficit(211,863)(158,010)
Accumulated other comprehensive loss(12,437)(15,670)
Total stockholders' equity14,06863,340
Total liabilities and stockholders' equity$77,992$126,644
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.